Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
SOPHIA ANTIPOLIS, France, April 17, 2015 (GLOBE NEWSWIRE) -- Nicox S.A. (Euronext Paris: FR0000074130, COX), the international ophthalmic company, today reported its first quarter 2015 revenues...
A year of strategic progress: Positive phase 3 results for Vesneo(TM) (Bausch + Lomb); NDA submission on track for Q2 2015 Significant strengthening of ophthalmic therapeutics...
SOPHIA ANTIPOLIS, France, March 19, 2015 (GLOBE NEWSWIRE) -- Nicox S.A. (Euronext Paris: COX) today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug...
InSite grants Nicox exclusive license for AzaSite® (1% azithromycin), BromSite(TM) (0.075% bromfenac) and AzaSite Xtra(TM) (2% azithromycin) in Europe, Middle East and...
SOPHIA ANTIPOLIS, France, Jan. 26, 2015 (GLOBE NEWSWIRE) -- Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced that it has held a positive pre-New Drug...
Nicox gains expanded North American rights for Sjö(TM) from Immco Diagnostics Nicox acquires extension of rights to market Sjö(TM) to all healthcare practitioners in North...
Nicox to focus US marketing resources on national roll-out of Sjö(TM) and launch of RetnaGene(TM) Rapid Pathogen Screening (RPS®) partnership for AdenoPlus® and two other...
Significant step forward in Nicox's strategy of creating an international ophthalmic company built around therapeutics and diagnostics Aciex brings a near-term pipeline of ophthalmic...
SOPHIA ANTIPOLIS, France, June 30, 2014 (GLOBE NEWSWIRE) -- Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced the launch of its German operations. Nicox...
SOPHIA ANTIPOLIS, France and SAN DIEGO, June 19, 2014 (GLOBE NEWSWIRE) -- Nicox and Sequenom announce the launch of expanded access to RetnaGene(TM) test portfolio in the U.S. June 19...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
